Inhibitors of inosine monophosphate dehydrogenase: SARs about the N-[3-Methoxy-4-(5-oxazolyl)phenyl moiety
摘要:
The first reported structure-activity relationships (SARs) about the N-[3-methoxy-4-(5-oxazolyi)phenyl moiety for a series of recently disclosed inosine monophosphate dehydrogenase (IMPDH) inhibitors are described. The syntheses and in vitro inhibitory values for IMPDH II, and T-cell proliferation (for select analogues) are given. (C) 2003 Elsevier Science Ltd. All rights reserved.
Inhibitors of inosine monophosphate dehydrogenase: SARs about the N-[3-Methoxy-4-(5-oxazolyl)phenyl moiety
摘要:
The first reported structure-activity relationships (SARs) about the N-[3-methoxy-4-(5-oxazolyi)phenyl moiety for a series of recently disclosed inosine monophosphate dehydrogenase (IMPDH) inhibitors are described. The syntheses and in vitro inhibitory values for IMPDH II, and T-cell proliferation (for select analogues) are given. (C) 2003 Elsevier Science Ltd. All rights reserved.
[EN] COMPOUNDS DERIVED FROM AN AMINE NUCLEUS THAT ARE INHIBITORS OF IMPDH ENZYME<br/>[FR] COMPOSES DERIVES D'UN NOYAU AMINE INHIBITEURS DE L'ENZYME IMPDH
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2000025780A1
公开(公告)日:2000-05-11
The present invention discloses the identification of the novel inhibitors of IMPDH (inosine-5'-monophosphate dehydrogenase). The compounds and pharmaceutical compositions disclosed herein are useful in treating or preventing IMPDH mediated diseases, such as transplant rejection and autoimmune diseases.
[EN] METABOLISM-MODULATING AGENTS AND USES THEREFOR<br/>[FR] AGENTS DE MODULATION DU MÉTABOLISME ET UTILISATIONS ASSOCIÉES
申请人:UNIV QUEENSLAND
公开号:WO2006017896A1
公开(公告)日:2006-02-23
The present invention is directed to methods and agents for modulating adipogenesis. More particularly, the present invention relates to molecules that modulate the level or functional activity of inosine-5' monophosphate dehydrogenase (IMPDH) and to their use in modulating the accumulation of lipids in adipocytes and/or the differentiation of preadipocytes to adipocytes for treating or preventing adiposity-related conditions including, but not limited to, obesity, lipoma, lipomatosis, cachexia or lipodystrophy or the loss of adipose tissue in trauma or atrophic conditions.